Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin

Chemotherapy

Volumn 51, Issue 4, 2005, Pages 186-192

  Van Rensburg, D J ^a   Fogarty, C ^b   Kohno, S ^c   Dunbar, L ^d   Rangaraju, M ^e   Nusrat, R ^e  

^a Medpark Centre   (South Africa)

^b Spartanburg Pharmaceutical Research ^*  (United States)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^e SANOFI   (France)

Author keywords

Community acquired pneumonia; Pneumococci; Resistance; Telithromycin

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN G; TELITHROMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL PROTOCOL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; TREATMENT OUTCOME;

EID: 26044442339     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086576     Document Type: Article

References (37)

1. British Thoracic Society Standards of Care Committee: BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 2001;56 (suppl 4):1-64.
2. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine AM: Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31: 347-382.
3. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Malory LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG: Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-1408.
4. Schito GC, Debbia EA, Marchese A: The evolving threat of antibiotic resistance in Europe: New data from the Alexander Project. J Antimicrob Chemother 2000;46(suppl T1):3-9.
5. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S81-S93.
6. Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(suppl 1):25-37.
7. Felmingham D: Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004;50(suppl 1):3-10.
8. Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239.
9. Felmingham D, Zhanel G, Hoban D: Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 2001;48(suppl T1):33-42.
10. Jones ME, Blosser-Middleton RS, Critchley IA, Thornsberry C, Sahm DF, Yamakita J, Akasaki M, Karlowsky JA: The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000. Chemotherapy 2002;48:232-237.
11. Barman Balfour JA, Figgitt DP: Telithromycin. Drugs 2001;61:815-829.
12. B resistance phenotype. J Antimicrob Chemother 1997;40:85-90.
13. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin. Antimicrob Agents Chemother 2000;44:414-417.
14. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E: Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378-386.
15. Dunbar L, Hassman J, Tellier G: Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62.
16. Pullman J, Chaplin, Vrooman PS: Efficacy and tolerability of telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia. Int J Clin Pract 2003;57:377-384.
17. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B: Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-523.
18. Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P: Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 2003;9:691-703.
19. Fogarty C, Patel TC, Galbraith H, Zuberbuhler GA, Leroy B: Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae (abstract 857). Abstracts 41st Intersci Conf Antimicrob Agents Chemother, Chicago, 2001. Washington, American Society for Microbiology, 2001, p 449.
20. van Rensburg DJ, Matthews PA, Leroy B: Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Opin Med Res 2002;18:397-400.
21. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, Niki Y, Kusano N: Clinical evaluation methods for new antimicrobial agents to treat respiratory tract infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother 1999;5:110-123.
22. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L: Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996;40:2562-2566.
23. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
24. Bryskier A: Ketolides - telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000;6:661-669.
25. Weisblum B: Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39:577-585.
26. Tait-Kamradt A, Clancy J, Cronan M, Dib-Hajj F, Wondrack L, Yuan W, Sutcliffe J: mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:2251-2255.
27. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam PR, Whitney CG: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001;286:1857-1862.
28. Fogarty C, Goldschmidt R, Bush K: Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31:613-615.
29. Lonks JR, Garau J, Gomez L, Tercavins M, Ochoa de Echaguen A, Garren IF, Reiss PT, Medeiros AA: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564.
30. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, Karlowsky JA: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002;34(suppl 1):S4-S16.
31. Hoban D, Waites K, Felmingham D: Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: Findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003;45:251-259.
32. Metlay JP: Update on community-acquired pneumonia: Impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002; 15:163-167.
33. Metlay JP, Singer DE: Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002;8(suppl 2):1-11.
34. Moellering RC Jr, Craig W, Edmond M, Farrell DJ, File TM Jr, Klein J, Lonks J, Metlay JP, Sahm D, Talbot GH: Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae. J Chemother 2002; 14(suppl 3):42-56.
35. Kelley, MA, Weber DJ, Gilligan P, Cohen MS: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-1011.
36. Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgenesen JH, La Magueres PL, Kraus KL: Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-631.
37. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN: Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-141.